Bayer Scores FDA-Approval for its CKD Drug Finerenone
Following a priority review, the USFDA finally gave its thumbs-up to Bayer AG’s Kerendia (finerenone) for chronic kidney disease (CKD) associated with type 2 diabetes (T2D) based on the results from the Phase III FIDELIO-DKD study.
Finerenone is the first and only non-steroidal mineralocorticoid receptor antagonist (MRA), which works by blocking the overactivation of the mineralocorticoid receptor that is associated with fibrosis and inflammation leading to permanent structural kidney damage.
The drug managed to improve cardiovascular and kidney outcomes by reducing the risk of kidney failure, heart ...
